<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/318B5D98-4CB4-4B10-A876-08FC93071A56"><gtr:id>318B5D98-4CB4-4B10-A876-08FC93071A56</gtr:id><gtr:name>King's College London</gtr:name><gtr:department>Gene and Cell Based Therapy</gtr:department><gtr:address><gtr:line1>Capital House</gtr:line1><gtr:line2>2nd Floor, Guys Campus</gtr:line2><gtr:line3>42 Weston Street</gtr:line3><gtr:line4>London</gtr:line4><gtr:postCode>SE1 3QD</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/318B5D98-4CB4-4B10-A876-08FC93071A56"><gtr:id>318B5D98-4CB4-4B10-A876-08FC93071A56</gtr:id><gtr:name>King's College London</gtr:name><gtr:address><gtr:line1>Capital House</gtr:line1><gtr:line2>2nd Floor, Guys Campus</gtr:line2><gtr:line3>42 Weston Street</gtr:line3><gtr:line4>London</gtr:line4><gtr:postCode>SE1 3QD</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/B31285F5-18A4-4A90-972F-EFC27BF69492"><gtr:id>B31285F5-18A4-4A90-972F-EFC27BF69492</gtr:id><gtr:firstName>Bernard</gtr:firstName><gtr:surname>Portman</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/1BE255AB-00BF-4AA3-9E28-22D1A5562980"><gtr:id>1BE255AB-00BF-4AA3-9E28-22D1A5562980</gtr:id><gtr:firstName>Michael</gtr:firstName><gtr:surname>Antoniou</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/271A1145-8759-4B2D-BA4C-7B7D8E3B1AAD"><gtr:id>271A1145-8759-4B2D-BA4C-7B7D8E3B1AAD</gtr:id><gtr:firstName>Hans-Joachim</gtr:firstName><gtr:surname>Lipps</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/569B5CE2-588D-48E3-90CE-F35335462F3C"><gtr:id>569B5CE2-588D-48E3-90CE-F35335462F3C</gtr:id><gtr:firstName>Helen</gtr:firstName><gtr:surname>Collins</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/78C6714F-401C-4088-895A-CD989942F477"><gtr:id>78C6714F-401C-4088-895A-CD989942F477</gtr:id><gtr:firstName>John</gtr:firstName><gtr:otherNames>William</gtr:otherNames><gtr:surname>Fabre</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0400866"><gtr:id>3AC2109F-C238-41D8-BADD-E4FFDBC27BFC</gtr:id><gtr:title>Liver-directed non-viral gene therapy for Wilson s disease</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0400866</gtr:grantReference><gtr:abstractText>Gene therapy is a novel and powerful approach to healthcare. Many 
inherited disorders will be cured by providing a normal copy of the 
defective gene. Gene therapy also has potential for treating complex conditions, e.g. chronic viral infections and autoimmune diseases.

Basic research must provide efficient and safe gene delivery techniques, 
and gene constructs which enable life-long expression of the therapeutic gene. 

This project involves Wilson?s disease, a hereditary disorder of copper metabolism. Patients are unable to excrete copper into bile, with con-
sequent copper accumulation in the liver, and liver disease. The LEC 
rat has a disorder identical to Wilson?s disease, due to a spontaneous mutation in the same gene as patients.

This project aims to define DNA constructs which will provide long-term expression of the Wilson?s gene in the livers of LEC rats. The effects of replacing the defective gene, especially normalisation of copper meta-
bolism and progression of liver scarring, will be carefully monitored.

This work would represent a major step forward towards the cure of Wilson?s disease, and act as a prototype for gene therapy of many other single gene disorders of the liver. It would also define gene therapy systems capable of broad application in liver disease.</gtr:abstractText><gtr:technicalSummary>Background
Wilson?s disease is an autosomal recessive disorder of copper metabolism, caused by a defective intracellular copper transporter (ATPase7b). Failure to excrete copper into bile results in accumulation in hepatocytes, with hepatocyte death and liver fibrosis. The Long Evans Cinnamon (LEC) rat has a spontaneous deletion in the ATPase7b gene, and is an excellent model of Wilson?s disease.

The biochemical defect, together with the large capacity of the liver for regeneration, means that gene-corrected hepatocytes have a survival advantage and will expand in the LEC liver. Moreover, the LEC liver is histologically normal at 8 weeks of age, but develops necrosis and fibrosis from ~10 weeks. The LEC rat is therefore an outstanding model for the stringent in vivo evaluation of episomal gene expression constructs, and for assessing gene therapy for Wilson?s disease.

The basic biology of cis-acting regulatory elements in episomal gene expression systems has advanced greatly. In vivo evaluation for non-viral gene therapy is now essential.

Objectives
1. To evaluate promising episomal plasmids for long-term gene expression and plasmid stability in vivo in the liver, under conditions of rapid expansion of gene-targeted cells.
2. To assess gene therapy for Wilson?s disease in the LEC rat model at two critical stages ? before the onset of liver pathology and in the face of existing liver pathology. 

Methodology
Three plasmids will be evaluated:
? The pMARs#9 plasmid carries critical elements of the Matrix Attachment Region of the human beta globin gene, and replicates once per mitosis.
? The pCET1010 plasmid carries a Ubiquitous Chromatin Opening Element.
? The pBS-HCRHPI-A plasmid carries a liver-specific Locus Control Region. 

An autologous rat reporter gene, intestinal lactase (not conferring a survival advantage) and rat ATPase7b cDNA, will be studied in these expression constructs.

Gene delivery will be to the right lateral lobe of LEC rats or normal DA rats, using the regional hydrodynamic approach via a branch of the portal vein.

Groups of rats will be assessed at days 1, 10, 30 and 100 for gene expression (lactase or ATPase7b), plasmid levels, expansion of gene-corrected hepatocytes, copper metabolism and histopathology.

Potential value 
Wilson?s disease is a serious single gene disorder. Its cure by gene therapy would represent an important milestone in the development of gene therapy in clinical practice. Of particular importance, these studies would define episomal gene expression systems broadly applicable to the gene therapy of liver and other diseases.</gtr:technicalSummary><gtr:fund><gtr:end>2008-10-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2005-07-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>314194</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>A CpG depleted expression plasmid</gtr:description><gtr:id>E225C2DD-7A59-400D-AC27-6FE1672B7EBF</gtr:id><gtr:impact>Longer term gene expression in liver has enabled progress towards transdifferentiating hepatocytes to pancreatic beta cells.</gtr:impact><gtr:outcomeId>nWt2kDaw8bJ</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>DNA expression construct</gtr:title><gtr:type>Technology assay or reagent</gtr:type></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>A4D4BBDD-B9EF-46C7-81F0-147BBE1E4A28</gtr:id><gtr:title>Intestinal lactase as an autologous beta-galactosidase reporter gene for in vivo gene expression studies.</gtr:title><gtr:parentPublicationTitle>Human gene therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d2f3c0cc5e96bb6370c90806cc3168a1"><gtr:id>d2f3c0cc5e96bb6370c90806cc3168a1</gtr:id><gtr:otherNames>Salehi S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1043-0342</gtr:issn><gtr:outcomeId>Kcf2w1uZYEE</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0400866</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>160D22D0-5677-4513-A0AC-7F3526B7F336</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Metabolic and Endocrine</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>DD81206B-5EB4-4BCC-AEF7-808A64606E0E</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>5.2  Cellular and gene therapies</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>